Protein microarrays offer a new means by which to conduct quantitative profiling of diseaseassociated proteins. The knowledge gained may provide novel strategies for early detection, diagnosis and therapeutic intervention. A variety of sophisticated approaches, including gene arrays, sequencing consortiums and large-scale two-dimensional gel electrophoresis, continue to generate lists of proteins potentially linked to disease aetiology and progression. The challenge is to evaluate quantitatively promising lead protein candidates using matched normal and diseased cell populations. In contrast to the antibody array, the reverse phase protein microarrays (RPPA) do not require labelling of cellular protein lysates, and constitute a sensitive high throughput platform for marker screening, pathophysiology investigation and therapeutic monitoring. In this paper, examples will be provided using RPPAs in the study of the apoptotic signalling cascade and in the evaluation of the expression of organ-specific protein makers using microdissected human organ cell lysates configured as 'human body arrays'.
INTRODUCTION
Gene expression profiling experiments have generated an unprecedented amount of information regarding concomitant genetic events during disease. [1] [2] [3] It is now widely accepted that the functional consequence of disease is manifested in the deregulation of protein products and protein networks that coalesce and break apart based on external and internal stimuli. These dynamic networks, in turn, propagate signals from the cell surface to the nucleus that ultimately determine the cell's fate. This information flow cannot be ascertained from gene expression analysis, as proteins are not simply invariant products of a gene but rather are dependent on highly regulated processes at the genetic, transcriptional, translational and post-translational level. 4, 5 The latter is a key determinant of diseased cellular physiology and may provide novel therapeutic and diagnostic targets. Building on the success of complementary DNA (cDNA) microarrays, there has been an increasing interest in developing protein microarrays that are capable of identifying hundreds of protein events simultaneously.
COMMON ISSUES TO BE CONSIDERED WHILE DEVELOPING PROTEIN MICROARRAYS
Protein arrays are designed to identify protein content, and protein-protein, protein-DNA or protein-ligand interactions. [6] [7] [8] [9] [10] [11] [12] Protein microarrays are fundamentally similar to cDNA microarrays in the fact that they are generated by placing nanolitres of a target molecule (eg recombinant proteins, antibodies or ligands) at spatially addressable regions onto planar surfaces, such as nitrocellulose, polyvinylidene fluoride (PVDF), poly-L-lysine, gel or chemically modified surfaces by either a pin-based or micro-dispensing arrayer.
Although protein microarrays utilise similar technologies routinely used to print cDNA arrays, a set of unique and challenging problems needs to be overcome if one wants to develop a robust protein microarray. Messenger RNA (mRNA) and cDNA are stable when immobilised and corresponding interactions are governed by WatsonCrick base pairing. Yet, in antibody arrays, for example, capture molecules are proteins themselves and tend to denature with change in pH or temperature. Furthermore, antigen-antibody interactions are determined by complex associations between epitope sites on the target protein and the antigen-binding site on the antibody and are also influenced by external conditions. Antibodies must exhibit strong affinities and specificity to each of their respective substrates, especially if one wants to investigate the activated state of specific proteins, such as phosphorylation, geranylation or proteolytic cleavage. Subsequently, activation-specific antibodies, routinely used in Western blots, may not be suitable in an array format, as the phosphorylation-specific site may be imbedded within the interior of the protein and thus not accessible to the antibody.
Quantification of protein concentrations presents the investigator with yet another problem if the aim is to analyse hundreds of antibody-antigen interactions on one array, as each antibody-antigen pair not only has its independent affinity constant, but the variation in protein concentrations in cells may be as high as six-fold. Thus, detection methods must be developed that quantify protein concentration over many orders of magnitude. The detection of antigen-antibody pairs is routinely performed by either sandwich assays in which two complementary antibodies to different sites of the protein are used, or by detecting a label on the protein itself. 8, 12 Conjugation of proteins may disturb the native folding structure of proteins and thus may destroy the antibody-antigen interaction, yielding false negatives.
PATHOGENIC ANALYSIS BY PROTEIN MICROARRAYS
Disease arises in a complex tissue microenvironment, and can be dramatically influenced by the physiological and immune state of the host. 13, 14 Consequently, a full understanding of the molecular basis of disease must ultimately be based on the pathological changes taking place in the actual target tissue. [15] [16] [17] With this aim in mind, array-based technologies have been developed to collect and array tissue samples for high throughput profiling. 6 In tissue arrays, punches are used to procure cores of fixed paraffin-embedded tissue, which are then precisely positioned into a 45 3 20 mm donor paraffin block. Hundreds of cores can be multiplexed and arrayed for further in situ hybridisation analyses. These arrays are well adapted for the qualitative surveillance of tumour and tissue specimens; however, they fail to provide a means to assess quantitative protein levels from specific cell populations of interest. Furthermore, because the punch diameters of each biopsy in tissue arrays are extremely small, they often miss branching ducts and glands dispersed in the tissue. Consequently, they cannot be used to study normal and pre-neoplastic epithelial cell populations, or cross-talk between diseased cells and adjacent host cells. In addition, edge effects, and fixation histories associated with each punch core biopsy, complicate the analysis and interpretation of immunohistochemistry.
REVERSE PHASE PROTEIN MICROARRAY AS A MEANS TO ASSESS QUANTITATIVE PROTEIN CHANGES IN DISEASED AND HEALTHY TISSUE
To circumvent these problems, the authors set out to develop a robust, sensitive and quantitative protein microarray that is applied to pure protein lysates isolated either from tissue or cultured cells. 18 Reverse phase protein microarrays (RPPAs) take advantage of two existing enabling technologies: laser capture microdissection (LCM) 19, 20 and microarray fabrication. 8, 21, 22 LCM is a high fidelity method to procure pure tissue cells of interest under direct microscopic visualisation. In LCM, the stained tissue slide is placed under a microscope, and the tissue is visualised in real time. A cap, housing an infra-red labile ethylene vinyl acetate (EVA) film, is placed onto the tissue, after which the user moves the slide to the area of interest. Firing of the laser melts an area with a diameter of 7.5-30 ìm. Subsequently, the molten polymer expands into the void of the stained tissue and solidifies within 200 ms, forming a 5 ìm mechanically strong polymer-tissue composite, 14 and the user has isolated the cells within the diameter of the laser. Following the firing, the user moves the slide until another set of cells is in the path of the laser, fires the laser and so on. After all cells have been procured, the transport arm is raised, shearing the tissue between the glass slide and the tissue-polymer composite, thereby separating isolated from non-isolated cells ( Figure 1 ).
To prepare RPPAs, histopathologically relevant pure cell populations are isolated by LCM and lysed; 700 pl of lysate is then immobilised in an array configuration via a pin-based microarrayer onto glassbacked nitrocellulose slides. These applications result in 350-500 ìm wide spots each containing the whole cellular protein repertoire corresponding to a given pathological state ( Figure 2 ). Subsequently, each slide can be probed with an antibody that can be detected by amplified fluorescent, colorimetric or chemiluminescent assays. The name 'reverse phase' is derived from the fact that this type of protein microarray immobilises the protein to be analysed. This is in contrast to conventional protein arrays that immobilise the antibody probe. 12 RPPA denatures the protein lysate prior to immobilisation and thus does not require labelling of the protein to be analysed. Because individual protein entities are present in femtomolar or lower concentrations, an amplification system had to be developed that allows for the specific and sensitive detection of proteins. We decided to utilise an amplification system that is based on catalysed receptor deposition (CARD). 18, 23 Over 1,000 individual cellular lysates can be accommodated on a 20 3 50 mm slide with 2 ìl of lysate ( Figure 3 ). The signal intensity (density) of each array spot is proportional to the concentration of the analyte member within the population of proteins immobilised on the spot. Relative quantitative comparisons of protein concentrations can be made within or between multiple study cases. Antibody-antigen interactions are highly dependent on the relative abundance of the antigen-antibody species as well as the binding affinities between the probe antibodies and the immobilised antigens. Consequently, protein samples are arrayed in miniature dilution curves to ensure that the analyte of interest remains within the linear range of detection. Such internal calibration is not possible for tissue fragment arrays or antibody arrays.
Similar to tissue arrays, multiple patients are represented on the array format, so that a molecular hypothesis can be tested on a series of cases to achieve statistical validity. RPPA was first originated with the aim of capturing microscopic stages of progressing cancer lesions within individual patients. 18 This was tested by applying RPPAs to the analysis of the state of protein signalling checkpoints involved in regulation of pro-survival and growth regulation during the transition from histologically normal epithelium to prostate intra-epithelial neoplasia and then to invasive carcinoma. The new technology provided direct quantitative evidence that suppression of apoptosis, via increase of phosphorylated Akt and concomitant decrease in activated Erk, in human pre-malignant and invasive prostate cancer may contribute to cancer cell survival by shifting the ratio of cell death to cell survival ( Figure 3 ). 18 Moreover, the same study also showed that downstream components of the apoptotic cascade (cleaved and noncleaved caspase-7, as well as cleaved and non-cleaved poly(ADP ribose) polymerase) are also shifted towards prosurvival function during cancer progression.
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APPLICATIONS OF RPPAs AS A TOOL TO INVESTIGATE SIGNAL TRANSDUCTION PATHWAYS
RPPAs can be used for diagnostic purposes, to analyse the status of signal transduction pathways or to validate potential vaccine candidates. This platform can be extended to any cell type and probed against any protein target. Examples are shown in Figures 4-6 . In Figure 4 , RPPAs were printed with unstimulated and cytochrome cstimulated Jurkat cells and probed against antibodies specific for the intrinsic pathway of the apoptotic cascade. The status of nodal caspases between treated and untreated cells can readily be determined with high sensitivity in such a parallel high throughput format. As expected, cleaved caspases are more prominent in cytochrome c-treated Jurkat cells compared with untreated cells. Similarly, RPPAs allow the monitoring of the relative activation status of proteins as a function of time or treatment, as shown in Figure 5 . In Figure 5 , Jurkat cells were treated with Fas Ligand (FasL) from 1 and 10 hours, and the relative activation status Figure 6 , is comprised of miniature dilution curves of tissue cell lysates that are prepared from microdissected pure organ parenchymal cells from major organs, such as brain, heart, lung, liver, kidney, prostate, testis and ovary. Antisera or specific antibodies recognising target antigens can be evaluated across multiple organs at once on each microarray. In this manner, crossreactivity and organ and/or tumour specificity can be quantitatively assessed and compared. When the array containing all representative organs is incubated with antibodies modelling a potential vaccine, the analysis may be able to predict the likelihood that the same organ specificity would be experienced within the treated subject.
To demonstrate feasibility of the human body array, the authors microdissected between 15,000 and 50,000 cells from normal human organ parenchymal epithelial cell populations that included brain, lung, heart, kidney, liver, prostate and testis, and arrayed between 2.5 and 7.5 cell equivalencies (depending on cell type) in two-fold dilution within discrete locations on the array. Normal organs were obtained from fresh autopsies. Each array was probed against an antibody specific for an organ type: (1) prostatic-specific antigen (PSA) for the prostate epithelium; (2) glial fibrillary acidic protein (GFAP) for brain neurones; and (3) myoglobin for the heart myocardium. As seen in Figure 7 , only the correct organ showed staining, with all other organ types remaining negative, demonstrating excellent specificity and high sensitivity.
DISCUSSION
Traditionally, the identification of new cancer-associated antigens or therapeutic targets has employed established proteomic methods such as twodimensional (2D) gel electrophoresis. Representative lysates of cancer cells and 24, 25 Nevertheless, individuals suffering from cancer respond differently to the same treatment even when they harbour similar tumours. Consequently, clinical oncologists have proposed that the likelihood of complete remission following treatment could be improved if the molecular effects of the treatment are monitored in real time using circulating tumour cells or metastatic lesions susceptible to sampling. Real-time monitoring also extends to the host Normal cells from brain, lung, heart, kidney, liver, prostate and testis were microdissected, arrayed and probed against organ-specific antibodies. Human body arrays were probed against: (A) glial fibrillary acidic protein (GFAP) for brain; (B) myoglobin for heart; and (C) prostaticspecific antigen (PSA) for prostate. Good specificity for each of the antibodies is achieved tissues. For example, it would be useful to monitor the status of lymphocyte signalling pathways in subjects undergoing experimental chemotherapy or immunotherapy. Evaluating the status of dysregulated proteins that are linked to drug responses or carcinogenesis, and extending these markers to host cellular signalling events, could advance and enable patient-tailored therapies and tumour-specific vaccines.
